8 research outputs found
Quantitative proteomics identify Tenascin-C as a promoter of lung cancer progression and contributor to a signature prognostic of patient survival
The extracellular microenvironment is an integral component of normal and diseased tissues that is poorly understood owing to its complexity. To investigate the contribution of the microenvironment to lung fibrosis and adenocarcinoma progression, two pathologies characterized by excessive stromal expansion, we used mouse models to characterize the extracellular matrix (ECM) composition of normal lung, fibrotic lung, lung tumors, and metastases. Using quantitative proteomics, we identified and assayed the abundance of 113 ECM proteins, which revealed robust ECM protein signatures unique to fibrosis, primary tumors, or metastases. These analyses indicated significantly increased abundance of several S100 proteins, including Fibronectin and Tenascin-C (Tnc), in primary lung tumors and associated lymph node metastases compared with normal tissue. We further showed that Tnc expression is repressed by the transcription factor Nkx2-1, a well-established suppressor of metastatic progression. We found that increasing the levels of Tnc, via CRISPR-mediated transcriptional activation of the endogenous gene, enhanced the metastatic dissemination of lung adenocarcinoma cells. Interrogation of human cancer gene expression data revealed that high TNC expression correlates with worse prognosis for lung adenocarcinoma, and that a three-gene expression signature comprising TNC, S100A10, and S100A11 is a robust predictor of patient survival independent of age, sex, smoking history, and mutational load. Our findings suggest that the poorly understood ECM composition of the fibrotic and tumor microenvironment is an underexplored source of diagnostic markers and potential therapeutic targets for cancer patients
Engraftment characterization of risk-stratified AML in NSGS mice
The authors thank Paola Romecin and Virginia Rodriguez-Cortez
for technical assistance.
This work was supported by the Spanish Ministry of Economy
and Competitiveness (SAF2016-80481R, PID2019-108160RBI00),
the Obra Social La Caixa (LCF/PR/HR19/52160011), Interreg
V-A programme (POCTEFA) 2014-2020 (grant PROTEOblood
EFA360/19), Health Canada (H4080-144541), and
Deutsche Josep Carreras Leukämie Stiftung (P.M.). Additional
funding was provided by Consejería de Salud y Familia (PI-
0119-2019) (R.D.d.l.G.), Health Institute Carlos III (ISCIII/FEDER, PI17/01028) and Asociación Española Contra el Cáncer (C.B.),
Health Institute Carlos III/FEDER (CPII17/00032) (V.R.-M.), and
Fundación Hay Esperanza (E.A.). CERCA/Generalitat de Catalunya
and Fundación Josep Carreras-Obra Social la Caixa provided
institutional support. B.L.-M. was supported by a Lady Tata Memorial
Trust International Award and Asociación Española Contra el
Cáncer (INVES20011LÓPE). O.M. and T.V.-H. were supported
by Asociación Española Contra el Cáncer (INVES211226MOLI)
and a Marie Sklodowska Curie Fellowship (792923), respectively.
P.M. is an investigator in the Spanish Cell Therapy Network.Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Disease
heterogeneity is well documented, and patient stratification determines treatment
decisions. Patient-derived xenografts (PDXs) from risk-stratified AML are crucial for
studying AML biology and testing novel therapeutics. Despite recent advances in PDX
modeling of AML, reproducible engraftment of human AML is primarily limited to high-risk
(HR) cases, with inconsistent or very protracted engraftment observed for favorable-risk
(FR) and intermediate-risk (IR) patients. We used NSGS mice to characterize the engraftment
robustness/kinetics of 28 AML patient samples grouped according to molecular/
cytogenetic classification and assessed whether the orthotopic coadministration of patientmatched
bone marrow mesenchymal stromal cells (BM MSCs) improves AML engraftment.
PDX event-free survival correlated well with the predictable prognosis of risk-stratified
AML patients. The majority (85-94%) of the mice were engrafted in bone marrow (BM)
independently of the risk group, although HR AML patients showed engraftment levels that
were significantly superior to those of FR or IR AML patients. Importantly, the engraftment
levels observed in NSGS mice by week 6 remained stable over time. Serial transplantation
and long-term culture-initiating cell (LTC-IC) assays revealed long-term engraftment limited
to HR AML patients, fitter leukemia-initiating cells (LICs) in HR AML samples, and the
presence of AML LICs in the CD342 leukemic fraction, regardless of the risk group. Finally,
orthotopic coadministration of patient-matched BM MSCs and AML cells was dispensable
for BM engraftment levels but favored peripheralization of engrafted AML cells. This
comprehensive characterization of human AML engraftment in NSGS mice offers a
valuable platform for in vivo testing of targeted therapies in risk-stratified AML patient
samples.Spanish Ministry of Economy
and Competitiveness (SAF2016-80481R, PID2019-108160RBI00)Obra Social La Caixa (LCF/PR/HR19/52160011)Interreg
V-A programme (POCTEFA) 2014-2020 (grant PROTEOblood
EFA360/19)Health Canada (H4080-144541)Deutsche Josep Carreras Leukämie StiftungConsejer ıa de Salud y Familia (PI-
0119-2019)Health Institute Carlos III (ISCIII/FEDER, PI17/01028)Asociación Española Contra el CáncerHealth Institute Carlos III/FEDER (CPII17/00032)Fundación Hay EsperanzaCERCA/Generalitat de CatalunyaFundació Josep Carreras-Obra Social la CaixaLady Tata Memorial
Trust International AwardAsociación Española Contra el
Cáncer (INVES20011LÓPE)Asociación Española Contra el Cáncer (INVES211226MOLI)Marie Sklodowska Curie Fellowship (792923
Engraftment characterization of risk-stratified AML in NSGS mice
Altres ajuts: Obra Social La Caixa (LCF/PR/HR19/52160011); Inter-reg V-A programme (POCTEFA) 2014-2020 (grant PROTEO-blood EFA360/19); Health Canada (H4080-144541); Deutsche Josep Carreras Leukamie Stiftung; Asociación Española Contra el Cáncer INVES20011LÓPE, INVES211226MOLI); Fundación Hay Esperanza; CERCA/Generalitat de Catalunya; Lady Tata Memorial Trust International Award.Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Disease heterogeneity is well documented, and patient stratification determines treatment decisions. Patient-derived xenografts (PDXs) from risk-stratified AML are crucial for studying AML biology and testing novel therapeutics. Despite recent advances in PDX modeling of AML, reproducible engraftment of human AML is primarily limited to high-risk (HR) cases, with inconsistent or very protracted engraftment observed for favorable-risk (FR) and intermediate-risk (IR) patients. We used NSGS mice to characterize the engraftment robustness/kinetics of 28 AML patient samples grouped according to molecular/ cytogenetic classification and assessed whether the orthotopic coadministration of patientmatched bone marrow mesenchymal stromal cells (BM MSCs) improves AML engraftment. PDX event-free survival correlated well with the predictable prognosis of risk-stratified AML patients. The majority (85-94%) of the mice were engrafted in bone marrow (BM) independently of the risk group, although HR AML patients showed engraftment levels that were significantly superior to those of FR or IR AML patients. Importantly, the engraftment levels observed in NSGS mice by week 6 remained stable over time. Serial transplantation and long-term culture-initiating cell (LTC-IC) assays revealed long-term engraftment limited to HR AML patients, fitter leukemia-initiating cells (LICs) in HR AML samples, and the presence of AML LICs in the CD342 leukemic fraction, regardless of the risk group. Finally, orthotopic coadministration of patient-matched BM MSCs and AML cells was dispensable for BM engraftment levels but favored peripheralization of engrafted AML cells. This comprehensive characterization of human AML engraftment in NSGS mice offers a valuable platform for in vivo testing of targeted therapies in risk-stratified AML patient samples
41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo.
Background Acute myeloid leukemia (AML) is a hematopoietic malignancy which is biologically, phenotypically and genetically very heterogeneous. Outcome of patients with AML remains dismal, highlighting the need for improved, less toxic therapies. Chimeric antigen receptor T-cell (CART) immunotherapies for patients with refractory or relapse (R/R) AML are challenging because of the absence of a universal pan-AML target antigen and the shared expression of target antigens with normal hematopoietic stem/progenitor cells (HSPCs), which may lead to life-threating on-target/off-tumor cytotoxicity. CD33-redirected and CD123-redirected CARTs for AML are in advanced preclinical and clinical development, and they exhibit robust antileukemic activity. However, preclinical and clinical controversy exists on whether such CARTs are myeloablative. Methods We set out to comparatively characterize in vitro and in vivo the efficacy and safety of 41BB-based and CD28-based CARCD123. We analyzed 97 diagnostic and relapse AML primary samples to investigate whether CD123 is a suitable immunotherapeutic target, and we used several xenograft models and in vitro assays to assess the myeloablative potential of our second-generation CD123 CARTs. Results Here, we show that CD123 represents a bona fide target for AML and show that both 41BB-based and CD28-based CD123 CARTs are very efficient in eliminating both AML cell lines and primary cells in vitro and in vivo. However, both 41BB-based and CD28-based CD123 CARTs ablate normal human hematopoiesis and prevent the establishment of de novo hematopoietic reconstitution by targeting both immature and myeloid HSPCs. Conclusions This study calls for caution when clinically implementing CD123 CARTs, encouraging its preferential use as a bridge to allo-HSCT in patients with R/R AML
The RNA-binding protein SERBP1 functions as a novel oncogenic factor in glioblastoma by bridging cancer metabolism and epigenetic regulation
Abstract
Background
RNA-binding proteins (RBPs) function as master regulators of gene expression. Alterations in RBP expression and function are often observed in cancer and influence critical pathways implicated in tumor initiation and growth. Identification and characterization of oncogenic RBPs and their regulatory networks provide new opportunities for targeted therapy.
Results
We identify the RNA-binding protein SERBP1 as a novel regulator of glioblastoma (GBM) development. High SERBP1 expression is prevalent in GBMs and correlates with poor patient survival and poor response to chemo- and radiotherapy. SERBP1 knockdown causes delay in tumor growth and impacts cancer-relevant phenotypes in GBM and glioma stem cell lines. RNAcompete identifies a GC-rich region as SERBP1-binding motif; subsequent genomic and functional analyses establish SERBP1 regulation role in metabolic routes preferentially used by cancer cells. An important consequence of these functions is SERBP1 impact on methionine production. SERBP1 knockdown decreases methionine levels causing a subsequent reduction in histone methylation as shown for H3K27me3 and upregulation of genes associated with neurogenesis, neuronal differentiation, and function. Further analysis demonstrates that several of these genes are downregulated in GBM, potentially through epigenetic silencing as indicated by the presence of H3K27me3 sites.
Conclusions
SERBP1 is the first example of an RNA-binding protein functioning as a central regulator of cancer metabolism and indirect modulator of epigenetic regulation in GBM. By bridging these two processes, SERBP1 enhances glioma stem cell phenotypes and contributes to GBM poorly differentiated state
41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo
Altres ajuts: We thank CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for their institutional support. PM acknowledges financial support from theSpanish Cancer Research Association (AECC-Semilla19), the Fundación Uno entre Cienmil, the Obra Social La Caixa (LCF/PR/HR19/52160011), the Leo Messi Foundation, the Banco Santander Foundation and the "Heroes hasta la médula" initiative.BACKGROUND: Acute myeloid leukemia (AML) is a hematopoietic malignancy which is biologically, phenotypically and genetically very heterogeneous. Outcome of patients with AML remains dismal, highlighting the need for improved, less toxic therapies. Chimeric antigen receptor T-cell (CART) immunotherapies for patients with refractory or relapse (R/R) AML are challenging because of the absence of a universal pan-AML target antigen and the shared expression of target antigens with normal hematopoietic stem/progenitor cells (HSPCs), which may lead to life-threating on-target/off-tumor cytotoxicity. CD33-redirected and CD123-redirected CARTs for AML are in advanced preclinical and clinical development, and they exhibit robust antileukemic activity. However, preclinical and clinical controversy exists on whether such CARTs are myeloablative. METHODS: We set out to comparatively characterize in vitro and in vivo the efficacy and safety of 41BB-based and CD28-based CARCD123. We analyzed 97 diagnostic and relapse AML primary samples to investigate whether CD123 is a suitable immunotherapeutic target, and we used several xenograft models and in vitro assays to assess the myeloablative potential of our second-generation CD123 CARTs. RESULTS: Here, we show that CD123 represents a bona fide target for AML and show that both 41BB-based and CD28-based CD123 CARTs are very efficient in eliminating both AML cell lines and primary cells in vitro and in vivo. However, both 41BB-based and CD28-based CD123 CARTs ablate normal human hematopoiesis and prevent the establishment of de novo hematopoietic reconstitution by targeting both immature and myeloid HSPCs. CONCLUSIONS: This study calls for caution when clinically implementing CD123 CARTs, encouraging its preferential use as a bridge to allo-HSCT in patients with R/R AML